Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $66 from $62 and keeps an Outperform rating on the shares after the company reported results and provided a business update. The firm is increasing its forecast for Q2 based on April monthly scripts of 3,776 reported by Pelthos on Thursday, and it remains optimistic on the continued growth trajectory heading into the summer months, which are associated with higher MC diagnosis and treatment.